Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Two Sigma Investments LP boosted its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 223.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,047 shares of the biotechnology company’s stock after buying an additional 82,254 shares during the period. Two Sigma Investments LP owned about 0.26% of Capricor Therapeutics worth $1,643,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Summit Investment Advisors Inc. lifted its holdings in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 1,345 shares during the period. The Manufacturers Life Insurance Company raised its position in Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,361 shares in the last quarter. Invesco Ltd. lifted its stake in Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 2,500 shares during the period. Russell Investments Group Ltd. boosted its holdings in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares in the last quarter. Finally, Corebridge Financial Inc. boosted its holdings in Capricor Therapeutics by 32.2% during the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 4,434 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $10.21 on Tuesday. The business has a fifty day moving average of $10.15 and a 200-day moving average of $13.05. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a market cap of $466.36 million, a PE ratio of -9.63 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the previous year, the business posted ($0.31) EPS. On average, analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Analysts Set New Price Targets

CAPR has been the subject of a number of recent research reports. Roth Capital initiated coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They issued a “buy” rating and a $31.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Finally, Wall Street Zen lowered shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $35.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.